November 19th, 2026What Wyden’s 2027 PBM Agenda Could Mean for Independent PharmaciesThe incoming Senate Finance majority can put PBMs back in the spotlight as Medicare develops new standards for pharmacy network contracts.Read more
November 17th, 2026Plan Churn, Claims Format Overhaul Loom for Pharmacies in 2027Owners believe clean plan-to-patient matching before January 1 is one of the simplest ways to protect cash flow in 2027.Read more
November 17th, 2026DOL Finalizes PBM Transparency Rule with Implications for Employers, Independent PharmaciesNew PBM compensation disclosures and audit rights could help employers spot reimbursement practices that hurt independent pharmacies, if they act.Read more
November 16th, 2026What Pharmacists Should Know About Shifting Peptide PolicyWith patients buying gray-market peptides, HHS’s draft policy aims to reunite prescribers, patients, and pharmacists around these emerging products.Read more
November 6th, 2026Missouri Challenges Lilly’s 340B Data Policy: What Stakeholders Should KnowAt the center of the debate are the growing number of manufacturer demands for claims data as a condition of 340B pricing. Read more
November 3rd, 2026PBM Audit Practices Under Scrutiny: What the House Inquiry Means for Independent PharmaciesThe inquiry puts audit practices, including how pharmacies are selected for audit, proportionality, and pharmacy advocacy in focus.Read more
November 20th, 2026Serotype 3 IPD Persists in Older Adults Despite PCV VaccinationPharmacists who vaccinate older adults face a serotype that current conjugate vaccines have yet to control.Read more
November 20th, 2026The Future of Obesity Care Pushing Beyond GLP-1 Drugs AloneAt ObesityWeek 2026, experts called GLP-1s a valuable tool and looked at what else patients need for lasting health, from new therapies to coverage and prevention.Read more